Research Progress Of Novel Vasodilators In Acute Heart Failure

Millions of patients worldwide are admitted for acute heart failure(AHF)each year.In recent decades,how to improve the clinical prognosis of AHF patients remains an enormous challenge to physicians.After diuretics,vasodilators are the most common intravenous therapy for AHF.Nevertheless,there is still a lack of enough evidences to demonstrate the efficacy of any currently available therapies for AHF in improving clinical outcomes.Recently,several novel agents with vasodilating properties have been developed for the treatment of AHF.These agents include soluble guanylate cyclase modulators,nitroxyl donors,natriuretic peptides and serelaxin P-arrestin-biased angiotensin II type 1 receptor ligands,aiming to improve both in-hospital and post-discharge clinical outcomes.